WO2000060943A1 - Prevention de lesions cerebrales liees a des accidents vasculaires cerebraux - Google Patents

Prevention de lesions cerebrales liees a des accidents vasculaires cerebraux Download PDF

Info

Publication number
WO2000060943A1
WO2000060943A1 PCT/US2000/010002 US0010002W WO0060943A1 WO 2000060943 A1 WO2000060943 A1 WO 2000060943A1 US 0010002 W US0010002 W US 0010002W WO 0060943 A1 WO0060943 A1 WO 0060943A1
Authority
WO
WIPO (PCT)
Prior art keywords
pro
val
ala
leu
human
Prior art date
Application number
PCT/US2000/010002
Other languages
English (en)
Inventor
Kevin J. Tracey
Haichao Wang
Original Assignee
North Shore-Long Island Jewish Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Shore-Long Island Jewish Research Institute filed Critical North Shore-Long Island Jewish Research Institute
Priority to US09/958,585 priority Critical patent/US7186555B1/en
Priority to EP00923342A priority patent/EP1191845A4/fr
Priority to JP2000610293A priority patent/JP2002541162A/ja
Priority to CA002368937A priority patent/CA2368937A1/fr
Priority to AU43485/00A priority patent/AU766910B2/en
Publication of WO2000060943A1 publication Critical patent/WO2000060943A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés et des compositions pharmaceutiques de la glycoprotéine humaine fétuine ou α2-HS glycoprotéine ou ses fragments utiles pour limiter les lésions tissulaires associées à l'ischémie, et plus particulièrement à des accidents vasculaires cérébraux ou à l'infarctus du myocarde.
PCT/US2000/010002 1999-04-13 2000-04-13 Prevention de lesions cerebrales liees a des accidents vasculaires cerebraux WO2000060943A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US09/958,585 US7186555B1 (en) 1999-04-13 2000-04-13 Prevention of brain damage in stroke
EP00923342A EP1191845A4 (fr) 1999-04-13 2000-04-13 Prevention de lesions cerebrales liees a des accidents vasculaires cerebraux
JP2000610293A JP2002541162A (ja) 1999-04-13 2000-04-13 発作による脳障害防止法
CA002368937A CA2368937A1 (fr) 1999-04-13 2000-04-13 Prevention de lesions cerebrales liees a des accidents vasculaires cerebraux
AU43485/00A AU766910B2 (en) 1999-04-13 2000-04-13 Prevention of brain damage in stroke

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12928899P 1999-04-13 1999-04-13
US60/129,288 1999-04-13

Publications (1)

Publication Number Publication Date
WO2000060943A1 true WO2000060943A1 (fr) 2000-10-19

Family

ID=22439301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010002 WO2000060943A1 (fr) 1999-04-13 2000-04-13 Prevention de lesions cerebrales liees a des accidents vasculaires cerebraux

Country Status (5)

Country Link
EP (1) EP1191845A4 (fr)
JP (1) JP2002541162A (fr)
AU (1) AU766910B2 (fr)
CA (1) CA2368937A1 (fr)
WO (1) WO2000060943A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1401471A2 (fr) * 2001-05-22 2004-03-31 Jenny Yu Composition et methode de traitement de cellules
US7344721B2 (en) * 1997-12-18 2008-03-18 David Tsai Polypeptide for the treatment of cancer and a method for preparation thereof
WO2021180884A1 (fr) 2020-03-11 2021-09-16 Universitaet Bern Fétuine a pour le traitement de troubles rénaux

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4426929B2 (ja) * 2004-03-25 2010-03-03 株式会社アミンファーマ研究所 脳卒中・無症候性脳梗塞のスクリーニング方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972924A (en) * 1995-01-20 1999-10-26 Maas Biolab, Llc Treatment of cerebral ischemia and cerebral damage with neuroprotective agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113164D0 (en) * 1991-06-18 1991-08-07 Ici Plc Pharmaceutical agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972924A (en) * 1995-01-20 1999-10-26 Maas Biolab, Llc Treatment of cerebral ischemia and cerebral damage with neuroprotective agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1191845A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344721B2 (en) * 1997-12-18 2008-03-18 David Tsai Polypeptide for the treatment of cancer and a method for preparation thereof
EP1401471A2 (fr) * 2001-05-22 2004-03-31 Jenny Yu Composition et methode de traitement de cellules
EP1401471A4 (fr) * 2001-05-22 2005-12-28 Jenny Yu Composition et methode de traitement de cellules
WO2021180884A1 (fr) 2020-03-11 2021-09-16 Universitaet Bern Fétuine a pour le traitement de troubles rénaux

Also Published As

Publication number Publication date
EP1191845A4 (fr) 2002-07-17
CA2368937A1 (fr) 2000-10-19
EP1191845A1 (fr) 2002-04-03
JP2002541162A (ja) 2002-12-03
AU766910B2 (en) 2003-10-23
AU4348500A (en) 2000-11-14

Similar Documents

Publication Publication Date Title
Schaefer et al. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction
DE60030173T2 (de) Neue Indikationen für Mannan-binding Lectin (MBL) zur Behandlung von immungeschwächten Patienten
US5508265A (en) Therapeutic uses of actin-binding compounds
EP0616536B1 (fr) Utilisation de décorine ou de biglycane pour la fabrication d'un médicament destiné au traitement de la pathologie associée au diabète
US7060680B2 (en) Morphogen treatments for limiting proliferation of epithelial cells
EP2875826A1 (fr) Composition pour la prévention ou le traitement d'une sepsie
Jiang et al. Monitoring of serum markers for fibrosis during CCl4-induced liver damage: Effects of anti-fibrotic agents
AU2013202269A1 (en) Compositions and methods for the treatment of fibrosis and fibrotic diseases
EP1154785B1 (fr) Inhibiteurs utilises dans l'hemostase et la fonction immunitaire
AU2018247928B2 (en) C4BP-based compounds for treating immunological diseases
AU766910B2 (en) Prevention of brain damage in stroke
EP1358888A1 (fr) L'Antibiotique peptidique humain LL-37/hCAP-18 est un inducteur de l'angiogénèse
WO1998004245A1 (fr) Utilisation de modulateurs de la transglutaminase pour favoriser la cicatrisation
US7186555B1 (en) Prevention of brain damage in stroke
RU2232594C2 (ru) Комплекс, содержащий ингибирующий остеокластогенез фактор (ocif) и полисахарид
US7592310B2 (en) Induction of antibiotic proteins and peptides by LAIT/sCD14-protein
RU2114120C1 (ru) Белок, связывающий инсулин-подобный фактор роста, фармацевтическая композиция
WO1997035609A1 (fr) Inhibiteur de la neoformation de vaisseaux sanguins renfermant un inhibiteur du mecanisme d'action du facteur tissulaire
Bao et al. Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes
Cao et al. Wedelolactone ameliorates synovial inflammation and cardiac complications in a murine model of collagen-induced arthritis by inhibiting NF-κB/NLRP3 inflammasome activation
EP0680334B1 (fr) Traitement d'ulceres gastro-intestinaux avec des morphogenes
Plager et al. Human eosinophil granule major basic protein and its novel homolog.
BG66395B1 (bg) Използване на il-18 инхибитори за лечение или предпазване от увреждания на централната нервна система
US8921312B2 (en) Combination of insulin and ascorbate to enhance wound healing
US6306824B1 (en) Uses of lipopolysaccharide binding protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2368937

Country of ref document: CA

Ref country code: CA

Ref document number: 2368937

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 610293

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000923342

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09958585

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000923342

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000923342

Country of ref document: EP